DiA Imaging Analysis/IBM Watson
The IBM (NYSE:IBM) Imaging AI Marketplace will offer DiA Imaging Analysis‘ FDA-cleared, AI-powered cardiac ultrasound software, designed to help clinicians analyze cardiac ultrasound images automatically rather than by visual interpretation.
IBM introduced DiA’s LVivo EF (ejection fraction) solution, which offers clinicians an AI-based quantification solution that will provide automated clinical data such as ejection fraction and global longitudinal strain (GLS).
IBM Watson said it plans to add other software to its AI Marketplace. Last August, IBM pushed back against reports that its artificial intelligence-powered products deliver less than promised, claiming that the reports are unfair and ignore its capabilities. A number of news outlets, including The Wall Street Journal and STAT News, published criticisms of IBM’s Watson Health offerings, claiming that its capabilities fall short of the company’s large promises.